A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus

• Safety and tolerability of PF-04937319 will be assessed by physical examinations, adverse event monitoring, 12 lead ECGs, continuous cardiac monitoring, vital sign, and safety laboratory measurements. [ Time Frame: ~4 months ] [ Designated as safety issue: Yes ]
• The single dose pharmacokinetics (PK) of PF-04937319 will be described by estimating parameters of AUCinf, AUClast, AUC24, Cmax, Tmax, CL/F, Vz/F and half life (t1/2), as the data permit. [ Time Frame: ~4 months ] [ Designated as safety issue: No ]

• Safety and tolerability of PF 04937319 will be assessed by physical examinations, adverse event monitoring, 12 lead ECGs, continuous cardiac monitoring, vital sign, and safety laboratory measurements. [ Time Frame: ~4 months ] [ Designated as safety issue: Yes ]
• The single dose PK of PF 04937319 will be described by estimating parameters of AUCinf, AUClast, AUC24, Cmax, Tmax, CL/F, Vz/F and half life (t1/2), as the data permit. [ Time Frame: ~4 months ] [ Designated as safety issue: No ]

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04937319 following single escalating oral doses in adult subjects with Type 2 Diabetes Mellitus (T2DM).

The purpose of this phase 1 study is to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF04937319 following single escalating oral doses in adult subjects with T2DM.

• Drug: Placebo
  Placebo to match PF-04937319 will be provided.
  Other Name: Placebo
• Drug: PF-04937319
  The initial planned dosing schedule is: 10, 30, 100, 200, and 400 mg, with one cohort to be determined. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as a single oral dose as a powder-in-capsule (PIC) formulation. PF-04937319 will be supplied as 10 mg and 80 mg (and potentially 1 mg) PIC.
  Other Name: PF-04937319

• Placebo Comparator: Placebo
  In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo.
  Intervention: Drug: Placebo
• Experimental: PF-04937319
  In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo. There will be approximately 6 dosing levels of PF-04937319
  Intervention: Drug: PF-04937319

Inclusion Criteria:

• Patients with type 2 diabetes mellitus who are taking stable doses of metformin only. Subjects treated with a sulfonylurea (SU) or a dipeptidyl peptidase-IV inhibitor (DPP-IVi) in combination with metformin may be eligible if washed off the SU or DPP-IVi to metformin only for a minimum of 4 weeks before dosing.
• Male and/or female subjects (females will be women of non childbearing potential) between the ages of 18 and 65 years, inclusive, with a body mass index (BMI) of 18.5 to 45.0 kg/m2 and C-peptide >0.8 ng/mL.
• Screening and Day -2 troponin I concentration </=0.05 ng/mL as measured by the Bayer Centaur Ultra assay.
• HbA1c >/=7% and </=11%. If the patient requires to be washed off an SU or DPP-IVi, the HbA1c limits will be >/=7% and </=9.5%.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Evidence or history of diabetic complications with significant end organ damage, eg, proliferative retinopathy and/or macular edema, creatinine clearance </=60 mL/min based on the Cockcroft-Gault equation, diabetic neuropathy complicated by neuropathic ulcers.
• History of stroke, transient ischemic attack, or myocardial infarction within the past 6 months. Additionally, history of coronary artery bypass graft or stent implantation, clinically significant peripheral vascular disease, or congestive heart failure (NYHA Classes II-IV). Furthermore, a current history of angina/unstable angina. Also, 12 lead electrocardiogram (ECG) demonstrating QTc >450 msec at screening, ECG findings suggestive of asymptomatic myocardial ischemia, or supine blood pressure >/=160 mm Hg (systolic) or </=100 mm Hg (diastolic).
• One or more self reported episodes of hypoglycemia within the last 3 months, or two or more self reported episodes of hypoglycemia within the last 6 months.
• Screening or Day -2 fasting (>/=8 hours) blood glucose, </=70 or >/=270 mg/dL, confirmed by a single repeat if deemed necessary.